Co-delivery of resolvin D1 and antibiotics with nanovesicles to lungs resolves inflammation and clears bacteria in mice

Gao, Jin; Wang, Sihan; Dong, Xinyue; Leanse, Leon G.; Wang, Zhenjia

doi:10.1038/s42003-020-01410-5

Cited by 53 publications

(39 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nanovesicles from neutrophils can specifically target inflamed endothelium in brain and lungs in order to treat stroke and acute lung inflammation (Dong et al, 2019 ; Gao et al, 2020 ). Nitrogen cavitation can rapidly disrupt cells to form pure nanovesicles from cell membrane (Gao et al 2016 ).…”

Section: Preclinical Studies Of Cell Membrane-camouflaged Biomimetic Nanoparticles Against Inflammationmentioning

confidence: 99%

“…In one study, incorporating resolvin D1 into the lipid bilayer of neutrophil membrane allowed such nanovesicles to adhere specifically to endothelial cells for the treatment of ischemic stroke lesions and lung infection (Gao et al, 2021). Resolvin D1 blocks infiltration by neutrophils and promotes the clearance of macrophages, helping to resolve inflammation (Gao et al, 2020(Gao et al, , 2021. These studies demonstrate that neutrophil membrane nanovesicles possess significant therapeutic potential for the treatment of inflammatory disorders.…”

Section: Nanoparticles Coated With Neutrophil Membranementioning

confidence: 99%

See 1 more Smart Citation

Recent advances in cell membrane-camouflaged nanoparticles for inflammation therapy

Zhang

Ding

et al. 2021

Drug Delivery

View full text Add to dashboard Cite

During inflammation, inflammatory cells are rapidly recruited to sites of infection or injury, where they cross physiological barriers around the infected site and further infiltrate into the tissues. Other cells, such as erythrocytes, endothelial cells and stem cells, also play prominent roles in host defense and tissue repair. In recent years, nanotechnology has been exploited to deliver drugs to sites of inflammation. For example, nanoparticles camouflaged with a cell membrane are a novel drug-delivery platform that can interact with the immune system and that show great potential for treating inflammation. Encapsulating drugs inside plasma membranes derived from various cells involved in inflammatory processes can be effective against inflammation. This review describes the preparation, characterization, and properties of various types of cell membrane-camouflaged biomimetic nanoparticles. It also summarizes preclinical research into their efficacy against inflammation.

show abstract

Section: Preclinical Studies Of Cell Membrane-camouflaged Biomimetic Nanoparticles Against Inflammationmentioning

confidence: 99%

Section: Nanoparticles Coated With Neutrophil Membranementioning

confidence: 99%

Recent advances in cell membrane-camouflaged nanoparticles for inflammation therapy

Zhang

Ding

et al. 2021

Drug Delivery

View full text Add to dashboard Cite

show abstract

“…Application of exogenous RvD1 reduced both bacterial growth and neutrophil infiltration, in both acute and long-term murine models of pneumonia [ 173 ]. While further studies of the therapeutic potential of resolvins are required in humans, these findings suggest that RvD1 may be a plausible therapeutic target in treating bacterial pneumonia due to its role in inhibiting inflammation and enhancing tissue healing in murine lung models [ 277 , 278 , 279 , 280 ]. To date, no human clinical trials with resolvins have been reported, but these compounds are well tolerated in mice [ 281 ].…”

Section: Therapeutic Interventions That Manipulate Efferocytosismentioning

confidence: 99%

Role of Apoptotic Cell Clearance in Pneumonia and Inflammatory Lung Disease

2021

View full text Add to dashboard Cite

Pneumonia and inflammatory diseases of the pulmonary system such as chronic obstructive pulmonary disease and asthma continue to cause significant morbidity and mortality globally. While the etiology of these diseases is highly different, they share a number of similarities in the underlying inflammatory processes driving disease pathology. Multiple recent studies have identified failures in efferocytosis—the phagocytic clearance of apoptotic cells—as a common driver of inflammation and tissue destruction in these diseases. Effective efferocytosis has been shown to be important for resolving inflammatory diseases of the lung and the subsequent restoration of normal lung function, while many pneumonia-causing pathogens manipulate the efferocytic system to enhance their growth and avoid immunity. Moreover, some treatments used to manage these patients, such as inhaled corticosteroids for chronic obstructive pulmonary disease and the prevalent use of statins for cardiovascular disease, have been found to beneficially alter efferocytic activity in these patients. In this review, we provide an overview of the efferocytic process and its role in the pathophysiology and resolution of pneumonia and other inflammatory diseases of the lungs, and discuss the utility of existing and emerging therapies for modulating efferocytosis as potential treatments for these diseases.

show abstract

“…This study reveals a new strategy to treat infectious diseases by designing nanoparticles to target inflammatory pathways and pathogens. ( Gao et al, 2020b ) ( Table 1 ).…”

Section: Resolvin D1 In Different Models Of Ardsmentioning

confidence: 99%

Resolvin D1, therapeutic target in acute respiratory distress syndrome

Molaei

Hayes

et al. 2021

European Journal of Pharmacology

View full text Add to dashboard Cite

Acute lung injury (ALI), or its more severe form, acute respiratory distress syndrome (ARDS), is a disease with high mortality and is a serious challenge facing the World Health Organization because there is no specific treatment. The excessive and prolonged immune response is the hallmark of this disorder, so modulating and regulating inflammation plays an important role in its prevention and treatment. Resolvin D1 (RvD1) as a specialized pro-resolving mediator has the potential to suppress the expression of inflammatory cytokines and to facilitate the production of antioxidant proteins by stimulating lipoxin A4 receptor/formyl peptide receptor 2 (ALX/FPR2). These changes limit the invasion of immune cells into the lung tissue, inhibit coagulation, and enhance cell protection against oxidative stress (OS). In particular, this biomolecule reduces the generation of reactive oxygen species (ROS) by blocking the activation of inflammatory transcription factors, especially nuclear factor-κB (NF-κB), and accelerating the synthesis of antioxidant compounds such as heme oxygenase 1 (HO-1) and superoxide dismutase (SOD). Therefore, the destruction and dysfunction of important cell components such as cytoplasmic membrane, mitochondria, Na+/k + adenosine triphosphatase (ATPase) and proteins involved in the phagocytic activity of scavenger macrophages are attenuated. Numerous studies on the effect of RvD1 over inflammation using animal models revealed that Rvs have both anti-inflammatory and pro-resolving capabilities and therefore, might have potential therapeutic value in treating ALI. Here, we review the current knowledge on the classification, biosynthesis, receptors, mechanisms of action, and role of Rvs in ALI/ARDS.

show abstract

Co-delivery of resolvin D1 and antibiotics with nanovesicles to lungs resolves inflammation and clears bacteria in mice

Cited by 53 publications

References 48 publications

Recent advances in cell membrane-camouflaged nanoparticles for inflammation therapy

Recent advances in cell membrane-camouflaged nanoparticles for inflammation therapy

Role of Apoptotic Cell Clearance in Pneumonia and Inflammatory Lung Disease

Resolvin D1, therapeutic target in acute respiratory distress syndrome

Contact Info

Product

Resources

About